Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor.
Goetz
Matthew P
MP
Departments of Oncology and Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.
D015415:Biomarkers; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D006801:Humans; D055118:Medication Adherence; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D057285:Precision Medicine; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism* / Q000627:therapeutic use; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use
D015415:Biomarkers; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C055492:4-hydroxy-N-desmethyltamoxifen; D019389:Cytochrome P-450 CYP2D6